Physician profile
Julia Harris
NPI 1326095605
$6,151.28
in general payments reported to CMS, 2019-2025
44 companies · $880 in 2025
The $880 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $538 · 2021: $975 · 2022: $752 · 2023: $1,312 · 2024: $1,083 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,275.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.05 | 2021-2025 | |
| Novo Nordisk INC | $660.50 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $553.06 | 2019-2022 | |
| Pfizer INC. | $509.54 | 2019-2025 | |
| Lilly USA, LLC | $455.82 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $438.37 | 2020-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Glaxosmithkline, LLC. | $245.07 | 2019-2025 | Shingrix, Arexvy |
| Amgen INC. | $178.28 | 2019-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $174.96 | 2019-2025 | Airsupra, Farxiga |
| Allergan, INC. | $171.45 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $168.03 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $148.34 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $120.20 | 2019-2025 | |
| Ibsa Pharma INC. | $100.52 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $99.39 | 2024-2025 | Voquezna |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $92.33 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $83.06 | 2023-2025 | Quviviq, Quviviq |
| Astellas Pharma US INC | $78.51 | 2019-2024 | Veozah |
| Hologic Sales and Service, LLC | $68.79 | 2019-2025 | Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.40 | 2022-2025 | Jascayd |
| Gilead Sciences, INC. | $53.91 | 2024-2025 | |
| Phadia US INC. | $49.57 | 2022-2025 | Immunocap |
| Organon LLC | $49.34 | 2023-2025 | Nexplanon |
| Exact Sciences Corporation | $46.86 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boston Scientific Corporation | $44.97 | 2023 | Wavewriter Alpha Prime 16 |
| Impel Pharmaceuticals INC. | $41.96 | 2023 | Trudhesa |
| Exeltis, USA INC. | $40.55 | 2023-2025 | Slynd |
| Avion Pharmaceuticals | $38.99 | 2019-2021 | |
| Seqirus USA INC | $38.94 | 2021-2024 | Flucelvax, Fluad |
| Genzyme Corporation | $37.38 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.31 | 2019-2024 | |
| Inari Medical, INC. | $33.65 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cranial Technologies, INC | $31.78 | 2019-2020 | |
| Amarin Pharma, INC. | $31.55 | 2019 | |
| Teleflex LLC | $27.73 | 2025 | Barrigel |
| Therapeuticsmd, INC. | $27.15 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.95 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.79 | 2019 | |
| Strongbridge US INC. | $21.44 | 2019 | |
| Optos, INC. | $16.86 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.35 | 2023 | Givlaari |
| Sumitomo Pharma America, INC. | $15.39 | 2024 | Gemtesa |
| Upsher-Smith Laboratories LLC | $15.19 | 2021 | |
| Coopersurgical, INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.